Elevated glucagon-like peptide-1-(7-36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 11, 2002, Pages 5191-5198

  Van Citters, Gregg W ^a,b   Kabir, Morvarid ^a,b   Kim, Stella P ^a,b   Mittelman, Steven D ^a,b   Dea, Melvin K ^a,b   Brubaker, Patricia L ^a,b   Bergman, Richard N ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DYSLIPIDEMIA; FAT INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC REGULATION; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; BLOTTING, NORTHERN; DIETARY FATS; DOGS; FASTING; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; GLUCOSE TOLERANCE TEST; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; OBESITY; PEPTIDE FRAGMENTS; RECEPTORS, GLUCAGON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ANIMALIA; CANIS FAMILIARIS;

EID: 0036845493     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020002     Document Type: Article

References (72)

1. Mayer-Davis EJ, Monaco JH, Hoen HM, Carmichael S, Vitolins MZ, Rewers MJ, Haffner SM, Ayad MF, Bergman RN, Karter AJ 1997 Dietary fat and insulin sensitivity in a triethnic population: The role of obesity. The Insulin Resistance Atherosclerosis Study (IRAS). Am J Clin Nutr 65:79-87
2. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP 1992 Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715-722
3. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C 1993 Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988-1992
4. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J 1995 Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273:1855-1861
5. Banting FG, Gairns S 1924 Factors influencing the production of insulin. Am J Physiol 68:24-30
6. McGarry JD 1998 Glucose-fatty acid interactions in health and disease. Am J Clin Nutr 67(3 Suppl):500S-504S
7. Ørskov C, Wettergren A, Holst JJ 1996 Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31:665-670
8. Toft-Nielsen MB, Madsbad S, Holst JJ 1999 Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143
9. Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KG 1999 Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of type II (non-insulin-dependent) diabetic parents: Evidence of several aberrations. Diabetologia 42:1314-1323
10. Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H 1999 Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J Nutr 129:46-50
11. Mittelman SD, Van Citters GW, Kim SP, Davis DA, Dea MK, Hamilton-Wessler M, Bergman RN 2000 Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced B-cell response. Diabetes 49:2116-2125
12. DeFronzo RA, Bonadonna RC, Ferrannini E 1992 Pathogenesis of NIDDM: A balanced overview. Diabetes Care 15:318-368
13. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C 1988 Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217-1225
14. Large V, Arner P 1998 Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabetes Metab 24:409-418
15. Boden G, Chen X, Rosner J, Barton M 1995 Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44:1239-1242
16. Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JD 1996 Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 97:2728-2735
17. Warnotte C, Gilon P, Nenquin M, Henquin JC 1994 Mechanisms of the stimulation of insulin release by saturated fatty acids. A study of palmitate effects in mouse β-cells. Diabetes 43:703-711
18. Zhou YP, Cockburn BN, Pugh W, Polonsky KS 1999 Basal insulin hypersecretion in insulin-resistant Zucker diabetic and Zucker fatty rats: Role of enhanced fuel metabolism. Metabolism 48:857-864
19. Stromblad G, Björntorp P 1986 Reduced hepatic insulin clearance in rats with dietary-induced obesity. Metabolism 35:323-327
20. Svedberg J, Stromblad G, Wirth A, Smith U, Björntorp P 1991 Fatty acids in the portal vein of the rat regulate hepatic insulin clearance. J Clin Invest 88:2054-2058
21. Wiesenthal SR, Sandhu H, McCall RH, Tchipashvili V, Yoshii H, Polonsky K, Shi ZQ, Lewis GF, Mari A, Giacca A 1999 Free fatty acids impair hepatic insulin extraction in vivo. Diabetes 48:766-774
22. Gelding SV, Niththyananthan R, Chan SP, Skinner E, Robinson S, Gray IP, Mather H, Johnston DG 1994 Insulin sensitivity in non-diabetic relatives of patients with non-insulin-dependent diabetes from two ethnic groups. Clin Endocrinol (Oxf) 40:55-62
23. Osei K, Cottrell DA, Bossetti B 1991 Relationships of obesity indices to serum insulin and lipoproteins in relatives of black patients with noninsulin-dependent diabetes mellitus (NIDDM). Int J Obes 15:441-451
24. Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F 1998 Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia 41:1127-1132
25. McIntyre N, Holdsworth CD, Turner DS 1964 New interpretation of oral glucose tolerance. Lancet 2:20-21
26. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W 1993 Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917
27. Jones IR, Owens DR, Luzio S, Williams S, Hayes TM 1989 The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32:668-677
28. Brynes AE, Frost GS, Edwards CM, Ghatei MA, Bloom SR 1998 Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition. Nutrition 14:433-436
29. Thomsen C, Rasmussen O, Lousen T, Holst JJ, Fenselau S, Schrezenmeir J, Hermansen K 1999 Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 69:1135-1143
30. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X 1999 Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331
31. Roust LR, Jensen MD 1993 Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes 42:1567-1573
32. Ørskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539
33. Toft-Nielsen M, Madsbad S, Holst JJ 1998 Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 41:1180-1186
34. Kong MF, Chapman I, Goble E, Wishart J, Wittert G, Morris H, Horowitz M 1999 Effects of oral fructose and glucose on plasma GLP-1 and appetite in normal subjects. Peptides 20:545-551
35. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, Giacca A 1999 Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48:1045-1053
36. Bergman RN, Phillips LS, Cobelli C 1981 Physiologic evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456-1467
37. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H 1996 A prospective analysis of the HOMA model. The Mexico City diabetes study. Diabetes Care 19:1138-1141
38. Haffner SM, Miettinen H, Stern MP 1997 The homeostasis model in the San Antonio Heart Study. Diabetes Care 20:1087-1092
39. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH 1989 Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1:1356-1359
40. Leahy JL 1990 Natural history of β-cell dysfunction in NIDDM. Diabetes Care 13:992-1010
41. Milburn Jr JL, Hirose H, Lee YH, Nagasawa Y, Ogawa A, Ohneda M, BeltrandelRio H, Newgard CB, Johnson JH, Unger RH 1995 Pancreatic β-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem 270:1295-1299
42. Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT 1998 Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes 47:1613-1618
43. Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, Turley SD, McGarry JD 1997 The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest 100:398-403
44. Newgard CB, McGarry JD 1995 Metabolic coupling factors in pancreatic β-cell signal transduction. Annu Rev Biochem 64:689-719
45. Zunz E, La Barre J 1929 Contributions a l'etudes des variations physiologiques de la secretion interne du pancreas: Relation entre les secretions externe et interne du pancreas. Arch Int Physiol Biochim 31:20
46. Unger RH, Eisentraut AM 1969 Entero-insular axis. Arch Intern Med 123:261-266
47. Habener JF 1993 The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am 22:775-794
48. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W 1986 Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498
49. Fried M, Mayer EA, Bloom SR, Taylor IL, Meyer JH 1989 GIP and insulin release in relation to gastric emptying of a mixed meal in man. Regul Pept 26:305-312
50. Baggio L, Kieffer TJ, Drucker DJ 2000 Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and non-enteral glucose clearance in mice. Endocrinology 141:3703-3709
51. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
52. Kolligs F, Fehmann HC, Göke R, Göke B 1995 Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19
53. Levin SR, Pehlevanian MZ, Lavee AE, Adachi RI 1979 Secretion of an insulinotropic factor from isolated, perfused rat intestine. Am J Physiol 236:E710-E720
54. Ebert R, Creutzfeldt W 1982 Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinology 111:1601-1606
55. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM 2000 Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med 17:713-719
56. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V 1993 Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute postprandial and 24-h secretion patterns. J Endocrinol 138:159-166
57. Persson K, Gingerich RL, Nayak S, Wada K, Wada E, Ahren B 2000 Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. Am J Physiol Endocrinol Metab 279:E956-E962
58. Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS 2000 Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 47:370-376
59. Fung LC, Chisholm C, Greenberg GR 1998 Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs. Endocrinology 139:189-194
60. Kawai K, Suzuki S, Ohashi S, Mukai H, Murayma Y, Yamashita K 1990 Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs. Acta Endocrinol (Copenh) 123:661-667
61. Wen J, Phillips SF, Sarr MG, Kost LJ, Holst JJ 1995 PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon. Am J Physiol 269:G945-G952
62. Solcia E, Fiocca R, Capella C, Usellini L, Sessa F, Rindi G, Schwartz TW, Yanaihara N 1985 Glucagon- and PP-related peptides of intestinal L cells and pancreatic/gastric A or PP cells. Possible interrelationships of peptides and cells during evolution, fetal development and tumor growth. Peptides 6(Suppl 3):223-229
63. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF 1987 Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438
64. Thorens B, Waeber G 1993 Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM. Diabetes 42:1219-1225
65. Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ 1998 Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47:632-639
66. Holz GG, Habener JF 1992 Signal transduction crosstalk in the endocrine system: Pancreatic β-cells and the glucose competence concept. Trends Biochem Sci 17:388-393
67. Dachicourt N, Serradas P, Bailbe D, Kergoat M, Doare L, Portha B 1997 Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent β-cells in diabetic rats: in vivo and in vitro studies. J Endocrinol 155:369-376
68. Kissler HJ, Gepp H, Schmiedl A, Schwille PO 1999 Preservation of the incretin effect after orthotopic pancreas transplantation in inbred rats. Metabolism 48:645-650
69. Nauck M, Stockmann F, Ebert R, Creutzfeldt W 1986 Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52
70. Madsbad S, Kehlet H, Hilsted J, Tronier B 1983 Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose. Diabetes 32:436-438
71. Faber OK, Madsbad S, Kehlet H, Binder C 1979 Pancreatic β cell secretion during oral and intravenous glucose administration. Acta Med Scand Suppl 624:61-64
72. Kjems LL, Kirby BM, Welsh EM, Veldhuis JD, Straume M, McIntyre SS, Yang D, Lefebvre P, Butler PC 2001 Decrease in β-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50:2001-2012